CA2092319A1 - Prolonging expression of polynucleotides introduced into a cell - Google Patents

Prolonging expression of polynucleotides introduced into a cell

Info

Publication number
CA2092319A1
CA2092319A1 CA002092319A CA2092319A CA2092319A1 CA 2092319 A1 CA2092319 A1 CA 2092319A1 CA 002092319 A CA002092319 A CA 002092319A CA 2092319 A CA2092319 A CA 2092319A CA 2092319 A1 CA2092319 A1 CA 2092319A1
Authority
CA
Canada
Prior art keywords
polynucleotide
cell
dna
hepatocytes
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002092319A
Other languages
English (en)
French (fr)
Inventor
George Y. Wu
Catherine H. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2092319A1 publication Critical patent/CA2092319A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002092319A 1990-09-25 1991-09-23 Prolonging expression of polynucleotides introduced into a cell Abandoned CA2092319A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US588,013 1984-03-09
US58801390A 1990-09-25 1990-09-25

Publications (1)

Publication Number Publication Date
CA2092319A1 true CA2092319A1 (en) 1992-03-26

Family

ID=24352098

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092319A Abandoned CA2092319A1 (en) 1990-09-25 1991-09-23 Prolonging expression of polynucleotides introduced into a cell

Country Status (5)

Country Link
EP (1) EP0556197A4 (ja)
JP (1) JPH06503714A (ja)
AU (1) AU8628291A (ja)
CA (1) CA2092319A1 (ja)
WO (1) WO1992005250A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2082507A1 (en) * 1990-05-11 1991-11-12 George Y. Wu Targeted protection from cytotoxins
ATE199647T1 (de) * 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
PT651805E (pt) * 1992-07-17 2007-02-28 Dana Farber Cancer Inst Inc Método de ligação intracelular de moléculas-alvo
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
JPH08508645A (ja) * 1993-04-05 1996-09-17 ユニバーシティ オブ コネティカット アンチセンスポリリボヌクレオチドをコードする遺伝子の標的を定めた送達
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
JPH0889278A (ja) * 1994-09-29 1996-04-09 Ajinomoto Co Inc 遺伝子導入用修飾蛋白質及びその製法
WO1996021036A2 (en) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
GB9907366D0 (en) * 1999-03-30 1999-05-26 Medical Res Council Method for expressing proteins

Also Published As

Publication number Publication date
EP0556197A1 (en) 1993-08-25
JPH06503714A (ja) 1994-04-28
EP0556197A4 (en) 1994-05-18
AU8628291A (en) 1992-04-15
WO1992005250A1 (en) 1992-04-02

Similar Documents

Publication Publication Date Title
Wu et al. Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo
AU728146B2 (en) Targeted delivery of genes encoding interferon
CA2103371C (en) Targeted delivery of genes encoding secretory proteins
CA2092319A1 (en) Prolonging expression of polynucleotides introduced into a cell
Trubetskoy et al. Use of N-terminal modified poly (L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells
US5656609A (en) Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
Huckett et al. Evidence for targeted gene transfer by receptor-mediated endocytosis: Stable expression following insulin-directed entry of neo into HepG2 cells
EP0532525B1 (de) Neue protein-polykation-konjugate
US6191257B1 (en) Natural or recombinant DNA binding proteins as carriers for gene transfer or gene therapy
WO1992019749A1 (en) Targeted delivery of genes encoding cell surface receptors
WO1997030731A2 (en) Method of preparing polynucleotide-carrier complexes for delivery to cells
AU4673901A (en) Peptide conjugates for drug delivery
EP0577648B1 (de) Neue protein-polykation-konjugate
US5744326A (en) Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
AU686614B2 (en) Targeted delivery of genes encoding antisense polyribonucleotides
Déas et al. In vivo-targeted gene delivery using antibody-based nonviral vector
US6479464B1 (en) Compositions and methods for highly efficient transfection
AU735667B2 (en) Targeted delivery of genes encoding secretory proteins
WO1998035984A2 (en) Compositions and methods for highly efficient transfection
WO1994028151A1 (en) Gene therapy for haemophilia
US20040009900A1 (en) Targeted delivery of genes encoding secretory proteins
WO1999015687A1 (en) Multicomponent polynucleotide complex for high efficiency cell transfection

Legal Events

Date Code Title Description
FZDE Dead